Table 3 Risk of Alzheimer’s disease by prescribed amount of strong anticholinergic agents.
Subjects | Prescribed amount (doses/year) | No. of AD events (%) | Incidence rate per 100,000 person-years | Crude model | Covariates model | |
|---|---|---|---|---|---|---|
Model I | Model II | |||||
Hazard ratio (95% Confidence interval) | ||||||
All subjects (n = 191,805) | overall | 13,133 (6.9) | 2.17 (2.13–2.21) | |||
0–9 | 5,863 (6.1) | 1.94 (1.90–1.99) | Reference | Reference | Reference | |
10–49 | 4,714 (6.6) | 2.08 (2.02–2.14) | 1.03 (0.99–1.07) | 1.02 (0.98–1.06) | 0.99 (0.95–1.03) | |
50–119 | 1,503 (9.5) | 3.01 (2.86–3.16) | 1.53 (1.44–1.61) | 1.28 (1.21–1.36) | 1.19 (1.12–1.26) | |
≥120 | 1,053 (12.1) | 3.87 (3.63–4.10) | 1.98 (1.86–2.12) | 1.57 (1.47–1.68) | 1.39 (1.30–1.50) | |
Young-old subgroup (n = 84,566) | overall | 2,542 (3.0) | 0.94 (0.90–0.98) | |||
0–9 | 1,032 (1.2) | 0.73 (0.69–0.78) | Reference | Reference | Reference | |
10–49 | 981 (3.1) | 0.97 (0.90–1.03) | 1.27 (1.17–1.39) | 1.18 (1.08–1.29) | 1.11 (1.04–1.22) | |
50–119 | 295 (5.0) | 1.56 (1.39–1.74) | 2.09 (1.83–2.37) | 1.70 (1.49–1.94) | 1.43 (1.25–1.65) | |
≥120 | 234 (7.6) | 2.39 (2.09–2.70) | 3.23 (2.81–3.73) | 2.47 (2.14–2.87) | 1.83 (1.56–2.14) | |
